Predicting Premature Treatment Termination in Inpatient Psychotherapy: A Machine Learning Approach
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06042595 |
Recruitment Status :
Completed
First Posted : September 18, 2023
Last Update Posted : September 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Premature Treatment Termination Dropout Prediction Inpatient Psychotherapy Machine Learning | Behavioral: Psychotherapy |
The aim of the study is to identify risk factors that lead to or predict premature treatment termination in psychosomatic hospitals. In the long-term, the study shall help to develop more precise prediction models that can enhance communication between therapists and patients about potential dropout and- if necessary- adaption of treatment in using a feedback loop.
Since it is still not clear which variables play a major role in predicting treatment termination in psychosomatic hospitals, the study design is exploratory and includes a broad range of intake patient characteristics. The purpose of this study is hereby, to develop a prediction model based on the information that are routinely assessed at intake. Therefore, three kind of variables are planned to be included: (1) demographic and other clinical variables (e.g. age, gender, ICD-10 diagnoses), (2) psychological questionnaire data (e.g. PHQ, SF-12, EB-45, IIP-32, OPD-SFK), and (3) physiological data (e.g. routine laboratory data, blood pressure). For the study, all patients that started inpatient psychotherapy at the medical centre Heidelberg between 2015 and January 2022 will be included, resulting in a sample size of approximately N = 2000. As the average dropout rate based on meta analytical results is around 20%, one can assume that up to 400 patients prematurely dropped out of treatment.
To calculate the prediction model, it is planned to use a machine learning approach which is highly functional in big data sets. Using a Random Forest Model for binary outcomes (regular treatment length vs. premature treatment termination) it is envisioned to identify variables that contribute to the prediction of premature treatment termination at intake. Additionally, waiting list effects will be considered by taking into account the waiting duration between the initial intake interview and the moment of the hospital admission. Therefore, the study will, for the first time, investigate a prediction model for premature treatment termination in inpatient psychotherapy including clinically relevant physiological data as well as waiting time effects in preparation of the psychosomatic treatment.
Study Type : | Observational |
Actual Enrollment : | 2023 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Predicting Premature Treatment Termination in Inpatient Psychotherapy: A Machine Learning Approach |
Actual Study Start Date : | January 2015 |
Actual Primary Completion Date : | January 2022 |
Actual Study Completion Date : | January 2022 |
- Behavioral: Psychotherapy
Patients treated at the inpatient psychotherapy unit of the University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers, and physiotherapists.
- Premature treatment termination (vs. treatment completion) [ Time Frame: Premature treatment termination will be operationalized as a dummy variable. Regular treatment duration is 8 weeks of inpatient psychotherapy. Data will be reported for 7 years of continuous study enrolment (01/2015 - 01/2022). ]Premature treatment termination will be classified based on the treatment duration. Classification will be made retrospectively for each patient based on the duration of the inpatient treatment and if applicable (duration < 49 days) on the hospital discharge letter to screen for reasons of the shorter treatment duration.
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- patients of at least 18 years of age
- included in inpatient psychotherapy treatment program in a hospital for psychosomatic medicine
- provided information about admission and discharge date
Exclusion Criteria:
- bipolar, acute psychotic or substance abuse disorder
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06042595
Study Director: | Ulrike Dinger-Ehrenthal, Prof. Dr. | Department of Psychosomatic Medicine and Psychotherapy, Medical Faculty, Heinrich-Heine University Düsseldorf |
Responsible Party: | Simone Jennissen, Principal Investigator, University Hospital Heidelberg |
ClinicalTrials.gov Identifier: | NCT06042595 |
Other Study ID Numbers: |
Dropout-Prediction-2023 |
First Posted: | September 18, 2023 Key Record Dates |
Last Update Posted: | September 18, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Individual participant data will not be shared because study data is provided by mental health patients and is therefore subject to strict protection. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Premature Birth Obstetric Labor, Premature Obstetric Labor Complications |
Pregnancy Complications Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |